But while the former auto tycoon is now safely ensconced in Lebanon, in one of his many homes, two of the men accused of helping him escape face trial in Tokyo.
The French-Lebanese-Brazilian national was eventually charged with four counts of financial misconduct over claims he hid compensation and misused Nissan funds.
Takeda Pharmaceutical jumped 3.18 percent to 3,793 yen after reports said its partner US biotech firm Moderna is planning to file for approval of its coronavirus vaccine in Japan as early as Friday.
The Taylor's lawyers in a late Thursday filing reiterated arguments that their clients could not be prosecuted in Japan for helping someone "bail jump" and that, if extradited.
The very least the US courts owe the petitioners is a full chance to litigate these issues, including exercising their appellate rights.
Nissan looks set to fall short of credits so it would either have to buy them from rivals, or step up its EV production. As buying credits would eat into profitability, it is favouring the second strategy, one of the sources said.
The group is likely to exit some unprofitable countries or markets, and has yet to reveal the line-up of cars it wants to entice customers with over the next three to eight years.
Like its Japanese alliance partner Nissan, Renault is rowing back on an aggressive expansion plan pursued by Carlos Ghosn, its former boss-turned-fugitive.
Ghosn is currently beyond the reach of the Japanese courts and leads a comparatively quiet life, mostly in his Beirut home, though he recently released a book setting out his side of his case.